Shaking Off Meeting Rust to Attend In-Person SOHO 2022
Just as we were getting used to attending conferences via virtual platforms, SOHO 2022 kicks off as an in-person meeting.
Just as we were getting used to attending conferences via virtual platforms, SOHO 2022 kicks off as an in-person meeting.
Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.
Yi-Bin Chen, MD, proposes a strategy to enhance patients’ quality of life by utilizing virtual monitoring as an alternative to requiring patients to travel to…
Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder cancer and unmet needs in this…
During a Case-Based Roundtable® event, Ruth M. O’Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a…
Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease…
During a Case-Based Roundtable® event, Ruth M. O’Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a…
The FDA has approved ColoSense, a stool screening test with 93% accuracy for colon cancer in average-risk adults over the age of 45. This noninvasive…
If approved, zenocutuzumab would be the first targeted therapy for neuregulin 1 fusion-positive lung and pancreatic cancers.
Dr. Kuykendall discusses the efficacy and safety findings from studies like MAJIC-PV and PROUD-PV, and how they influence his treatment choices for PV.
In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for…